Insider Transactions in Q4 2024 at Apellis Pharmaceuticals, Inc. (APLS)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2024
|
Timothy Eugene Sullivan Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,096
+5.65%
|
$155,344
$14.4 P/Share
|
|
Dec 23
2024
|
Jeffrey Eisele Chief Development Officer |
SELL
Open market or private sale
|
Direct |
63
-0.11%
|
$2,079
$33.09 P/Share
|
|
Dec 11
2024
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
5,000
-4.25%
|
$170,000
$34.23 P/Share
|
|
Nov 01
2024
|
Cedric Francois Chief Executive Officer |
SELL
Other acquisition or disposition
|
Indirect |
182,146
-27.84%
|
-
|